ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 667

Urinary Metabolomic Fingerprint As Diagnostic Biomarker for Clinical Significant Lupus Nephritis

David Herrera Van Oostdam1, Rogelio Flores Ramirez2, Maribel Rodriguez Aguilar2, Mauricio Pierdant Pérez3, Carlos Abud-Mendoza4, David Martínez-Galla5 and Marco Ulises Martinez-Martinez6, 1Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 22. Coordinación para la Innovación y Aplicación de la Ciencia y la Tecnología, San Luis Potosí, San Luis Potosi, Mexico, 3Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico, 4Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, 5Pathology, Hospital Central "Dr. Ignacio Morones Prieto", San Luis Potosí, Mexico, 6Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: , ,

Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

–Background/Purpose: Lupus nephritis (LN) represents the main prognostic factor in systemic lupus erythematosus (LES) [1]. The clinical significant classes of LN –due to the need of treatment- are the proliferative (III, IV), membranous (V) and mixed classes (III or IV/V). The aim of the study was to find a urinary metabolomic fingerprint to diagnose classes III, IV and/or V of LN

–Methods: Cross-sectional study. Inclusion criteria: lupus patients with and without clinical significant lupus nephritis (classes III, IV, V and mixed classes). Urine samples were screened for metabolites using gas chromatography mass spectrometry (coupled with electronic nose) and principal component analysis for metabolite selection.

–Results: We included 29 lupus patients, 11 with LN and 18 without LN. Age between groups were 26 years (IQR 14.5) in patients with LN and 33 (IQR 22.3) in patients without LN (p 0.48). The median SLEDAI score in LN patients was of 13 and 3 in those without NL (p <0.0001). Class IV nephritis was present in 45% of LN patients, mixed class in 36%, and class V in 18%. The median proteinuria of patients with NL was 1g/L, (IQR 2.7). We observed differences in metabolic fingerprint in patients with and without LN, with an AUC 90%. Metabolic pathway analysis was conducted, and we found several pathways involved, like methane, glycolysis, pyruvate and glycerophospholipid pathways. The most significant metabolites of the PCA that discriminated LN, were 2-nonanone with a sensitivity of 0.87 and specificity of 0.93. Obtaining the ratio of 2-bromopropane with 2-nonanone, the diagnostic accuracy improved, with a positive likelihood ratio (LR) of 14 and a negative LR of 0.1.

–Conclusion: We identified a urinary metabolomic fingerprint that involved several metabolic pathways; 2-nonanone and the ratio of 2-bromopropane/2-nonanone had the best diagnostic accuracy in our study.

-References: 1. Mok CC, Kwok RCL, Yip PSF. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:2154–60

Disclosure: D. Herrera Van Oostdam, None; R. Flores Ramirez, None; M. Rodriguez Aguilar, None; M. Pierdant Pérez, None; C. Abud-Mendoza, Bristol-Myers Squibb, Pfizer Inc, Roche, 5,Bristol-Myers Squibb, Merck-Serono, Pfizer Inc, Roche, UCB, 8; D. Martínez-Galla, None; M. U. Martinez-Martinez, None.

To cite this abstract in AMA style:

Herrera Van Oostdam D, Flores Ramirez R, Rodriguez Aguilar M, Pierdant Pérez M, Abud-Mendoza C, Martínez-Galla D, Martinez-Martinez MU. Urinary Metabolomic Fingerprint As Diagnostic Biomarker for Clinical Significant Lupus Nephritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/urinary-metabolomic-fingerprint-as-diagnostic-biomarker-for-clinical-significant-lupus-nephritis/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urinary-metabolomic-fingerprint-as-diagnostic-biomarker-for-clinical-significant-lupus-nephritis/